Remove Biomarkers Remove Circulation Remove Hypertension
article thumbnail

Circulating miRNA-486 as a novel diagnostic biomarker for right ventricular remodeling

Frontiers in Cardiovascular Medicine

ObjectiveClinical practice currently faces a significant shortfall in specific biomarkers needed for diagnosing right ventricular (RV) remodeling in patients with pulmonary hypertension (PH). MiRNA sequencing analyses revealed 19 dif-miRNAs (12 upregulated and 7 downregulated) between the two groups.

article thumbnail

Ultrasound Neuromodulation Shows Promise to Treat Pulmonary Hypertension, Feinstein Institutes Research

DAIC

Bioelectronic medicine scientists at The Feinstein Institutes for Medical Research used noninvasive, splenic focused ultrasound stimulation (sFUS) and found they can reduce inflammation and improve symptoms of pulmonary arterial hypertension (PAH). For years, Dr. Zanos has investigated bioelectronic medicine therapies to treat PAH.

article thumbnail

Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

DAIC

Results of Tenax Therapeutics’ Phase 2 HELP study of levosimendan in patients with pulmonary hypertension (PH) with heart failure with preserved ejection fraction (HFpEF) demonstrated that I.V. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,

article thumbnail

Comprehensive Proteomics Profiling Identifies Circulating Biomarkers to Distinguish Hypertrophic Cardiomyopathy from Other Cardiomyopathies with Left Ventricular Hypertrophy

Circulation: Heart Failure

Circulation: Heart Failure, Ahead of Print. Background:Distinguishing hypertrophic cardiomyopathy (HCM) from other cardiomyopathies with left ventricular hypertrophy (LVH), such as hypertensive LVH, transthyretin amyloid cardiomyopathy (ATTR-CM), and aortic stenosis (AS), is sometimes challenging. and |log2(fold change)| >0.5

article thumbnail

Investigators identify novel plasma proteins linked to future risk of hypertension

Medical Xpress - Cardiology

For example, blood pressure changes during exercise (EBP) can reveal a latent tendency toward future development of hypertension. At present, there is no reliable circulating biomarker—a protein or other molecule present in the blood stream—indicative of hypertension risk.

article thumbnail

Albuminuria in Cardiovascular, Kidney, and Metabolic Disorders: A State-of-the-Art Review

Circulation

Circulation, Volume 151, Issue 10 , Page 716-732, March 11, 2025. Albuminuriaincreased urine albumin excretionis associated with cardiovascular mortality among patients with diabetes, hypertension, chronic kidney disease, or heart failure, as well as among adults with few cardiovascular risk factors.

article thumbnail

Abstract 4144785: Identification of ARMCX3 as potential mitochondria-related biomarker for pulmonary arterial hypertension using integrated bioinformatics analysis and machine learning

Circulation

Circulation, Volume 150, Issue Suppl_1 , Page A4144785-A4144785, November 12, 2024. Background:Acquired mitochondrial dysfunction is one of the characteristics of pulmonary arterial hypertension (PAH). Exploring potential biomarkers from mitochondrial perspective may be effective in the diagnosis and treatment of PAH.